|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||
| Cash | ||||||||||
| Prepaid expenses | ||||||||||
| Prepaid insurance | ||||||||||
| Total current assets | ||||||||||
| Cash and marketable securities held in Trust Account | ||||||||||
| Long-term prepaid insurance | ||||||||||
| Marketable securities held in Trust Account | ||||||||||
| Total Assets | ||||||||||
| Current liabilities | ||||||||||
| Accrued expenses | ||||||||||
| Accrued offering costs | ||||||||||
| Due to shareholders | ||||||||||
| Promissory note - related party | ||||||||||
| Total current liabilities | ||||||||||
| Deferred legal fees | ||||||||||
| Deferred Fee payable | ||||||||||
| Deferred legal fees | ||||||||||
| Deferred Fee payable | ||||||||||
| Total Liabilities | ||||||||||
| Class A Ordinary Shares subject to possible redemption, 18,496,164 and 23,000,000 shares at redemption value of $10.99 and $10.70 per share as of September 30, 2026 and December 31, 2025, respectively | ||||||||||
| Shareholders’ Deficit | ||||||||||
| Ordinary shares value | ||||||||||
| Class A Ordinary Shares | ||||||||||
| Class B Ordinary Shares | ||||||||||
| Accumulated deficit | ||||||||||
| Total Shareholders’ Deficit | ||||||||||
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...